Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by lv_426on Jun 15, 2020 9:38pm

71 Views

Post# 31153881

RE:RE:NR Today

Ingiboy wrote: Well I guess we were right, they are insolvent. Not enough money to do their yearend audit.
This is pitiful.
No mention of the status of the Dermal Injector or any other pertinent information on the company.

This is a very disturbing turn of events. They once again have to go begging for money to keep the company going. Instead of releasing the much vaunted Dermal Injector and have numerous companies lining up to distribute it they are close to insolvency.

Based on what replicel(Lee) has done in the past who in their right mind would give money to this company? With is current economic climate there really any isn't free cash kicking around

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects